Table 1 The clinical and pathological characteristics of three male breast cancer patients
From: The clinical manifestations and treatment of male breast cancer: a report of three cases
Case | Age | Tumor size (mm) | T | N | M | Stage | Histology | Nuclear grade | ER | PgR | HER2 | Ki67 | Adjuvant therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 64 | 10 | 1 | 0 | 0 | I | Solid-tubular carcinoma | 1 | + | + | 0 | Unknown | Tamoxifen 20 mg |
2 | 64 | 16 | 1 | 0 | 0 | I | Solid-tubular carcinoma | 1 | + | + | 0 | Unknown | Tamoxifen 20 mg |
3 | 69 | 24 | 2 | 1 | 0 | IIB | Scirrhous carcinoma | 3 | + | + | 0 | 21.2 % | Taxotere (75 mg/m2) and cyclophosphamide (600 mg/m2) |
Tamoxifen (20 mg) |